Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome

DiGeorge Syndrome Clinical Trial

Official title:

Genetic Modifiers of 22q11.2 Deletion Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00556530
• Other study ID #: 1999-201
• Secondary ID: R01HL084410
• Status: Recruiting
• Start date: July 2016
• Est. completion date: July 2029

Study information

• Verified date: June 2023
• Source: Albert Einstein College of Medicine
• Contact: Bernice E. Morrow, PhD
• Phone: 718-678-1121
• Email: morrow[@]aecom.yu.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.

Description:

22q11.2 deletion syndrome is a disorder caused by the deletion of a small piece of chromosome 22. Most people with this disorder are missing a sequence of about 3 million DNA building blocks on chromosome 22 within each cell. This disorder affects many areas of the body. People with 22q11.2 deletion syndrome may have heart defects, immune deficiency, kidney abnormalities, hearing loss, and cleft palate or other facial deformities. Many children experience developmental delays and learning disabilities, and they have an increased risk of developing mental illnesses, including schizophrenia, depression, anxiety, and bipolar disorder. All people with 22q11.2 deletion syndrome are missing the same sequence of DNA, but the severity of this disorder varies widely; some people are diagnosed with multiple health and developmental problems, while others experience very few symptoms. In some people, the symptoms may be so minimal that they are not even aware they have 22q11.2 deletion syndrome. This study will examine genetic material-either from blood or saliva-among people with 22q11.2 deletion syndrome. Participants will attend one study visit and undergo either blood or saliva collection. By analyzing the DNA sequences of participants, the study will aim to identify any genetic variations that may affect the severity of 22q11.2 deletion syndrome.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: July 2029
• Est. primary completion date: June 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Has 22q11 deletion of 3 megabases (Mb)

Exclusion Criteria:

• Has 22q11 deletion smaller than 3 Mb or no deletion

Related Conditions & MeSH terms

• 22q11.2 Deletion Syndrome
• DiGeorge Syndrome
• Syndrome

Locations

Country	Name	City	State
United States	Albert Einstein College of Medicine	New York	New York
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Albert Einstein College of Medicine	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States,